DNTH Dianthus Therapeutics, Inc.
DNTH Dianthus Therapeutics, Inc.
Healthcare · Biotechnology
Desk view
Market read
Scan convergence 1 scan as of 2026-10-16 1 neutral converging
POC $83.97 · VWAP $76.12 · -5.3% vs 12m avg buyer
Insiders selling 0 buy / 1 sell · Form 4, 90d $17.9M sold last open-market sell Garcia Marino
Cluster CEO, SVP + 2 others sold $21.6M, Aug 7–19
Coverage
1 watchlist
DNTH Price Structure
Loading timeframes…
Peers
Every watchlist DNTH belongs to, members best 30-day change first — DNTH highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Reported the quarter ending 2026-06-30: diluted EPS -$0.90, net income -$50M (SEC filing). Across the print the stock moved -3.2% (close before → first close after).
full note →Against street estimates
How DNTH's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about DNTH from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 1 day ago · Oct 16
- Dianthus Therapeutics Stock Price | DNTH Stock Quote, News, and History | Markets Insider
- Investor Relations - Dianthus Therapeutics
- Stock Quote & Chart - Dianthus Therapeutics
- Dianthus Therapeutics Inc Stock Price Today | NASDAQ: DNTH Live - Investing.com
- Dianthus Therapeutics (DNTH) Q2 2026 Earnings Results & Report
DNTH research tape
86 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.